Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs

Shyamal C. Das, Peter J. Stewart

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

4 Citations (Scopus)

Abstract

This chapter considers the respiratory delivery of drugs used in the treatment of tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis. It provides a rationale for respiratory delivery of anti-tubercular drugs to the lungs, including the targeting of alveolar macrophages and granulomas. The doses of anti-tubercular drugs are high and most formulations will be carrier free containing drug and limited amounts of excipient. The aerosolization of high dose drugs existing in a cohesive matrix will be related to de-agglomeration processes. The chapter outlines the studies that have occurred in this area using particle engineering approaches. Formulations of particles or engineered particles which possess a suitable size for respiratory delivery can be considered as cohesive matrices. The particles in the matrix will interact due to the various interactive forces that exist between particles, including contact potential forces, Coulombic forces, intermolecular forces, capillary force and solid bridging.

Original languageEnglish
Title of host publicationDrug Delivery Systems for Tuberculosis Prevention and Treatment
EditorsAnthony J. Hickey, Amit Misra, P. Bernard Fourie
Place of PublicationChichester West Sussex UK
PublisherJohn Wiley & Sons
Pages258-274
Number of pages17
Edition1st
ISBN (Electronic)9781118943182
ISBN (Print)9781118943175
DOIs
Publication statusPublished - 26 Aug 2016

Publication series

NameAdvances in Pharmaceutical Technology
PublisherJohn Wiley & Sons, Ltd

Keywords

  • Anti-tubercular drugs
  • Carrier free containing drug
  • Cohesive matrix
  • De-agglomeration processes
  • Mycobacterium tuberculosis
  • Particle engineering approaches
  • Respiratory delivery

Cite this

Das, S. C., & Stewart, P. J. (2016). Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs. In A. J. Hickey, A. Misra, & P. B. Fourie (Eds.), Drug Delivery Systems for Tuberculosis Prevention and Treatment (1st ed., pp. 258-274). (Advances in Pharmaceutical Technology). Chichester West Sussex UK: John Wiley & Sons. https://doi.org/10.1002/9781118943182.ch13
Das, Shyamal C. ; Stewart, Peter J. / Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs. Drug Delivery Systems for Tuberculosis Prevention and Treatment. editor / Anthony J. Hickey ; Amit Misra ; P. Bernard Fourie. 1st. ed. Chichester West Sussex UK : John Wiley & Sons, 2016. pp. 258-274 (Advances in Pharmaceutical Technology).
@inbook{4cef695b798c4027b739bf65d554bf63,
title = "Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs",
abstract = "This chapter considers the respiratory delivery of drugs used in the treatment of tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis. It provides a rationale for respiratory delivery of anti-tubercular drugs to the lungs, including the targeting of alveolar macrophages and granulomas. The doses of anti-tubercular drugs are high and most formulations will be carrier free containing drug and limited amounts of excipient. The aerosolization of high dose drugs existing in a cohesive matrix will be related to de-agglomeration processes. The chapter outlines the studies that have occurred in this area using particle engineering approaches. Formulations of particles or engineered particles which possess a suitable size for respiratory delivery can be considered as cohesive matrices. The particles in the matrix will interact due to the various interactive forces that exist between particles, including contact potential forces, Coulombic forces, intermolecular forces, capillary force and solid bridging.",
keywords = "Anti-tubercular drugs, Carrier free containing drug, Cohesive matrix, De-agglomeration processes, Mycobacterium tuberculosis, Particle engineering approaches, Respiratory delivery",
author = "Das, {Shyamal C.} and Stewart, {Peter J.}",
year = "2016",
month = "8",
day = "26",
doi = "10.1002/9781118943182.ch13",
language = "English",
isbn = "9781118943175",
series = "Advances in Pharmaceutical Technology",
publisher = "John Wiley & Sons",
pages = "258--274",
editor = "Hickey, {Anthony J.} and Amit Misra and Fourie, {P. Bernard}",
booktitle = "Drug Delivery Systems for Tuberculosis Prevention and Treatment",
address = "United States of America",
edition = "1st",

}

Das, SC & Stewart, PJ 2016, Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs. in AJ Hickey, A Misra & PB Fourie (eds), Drug Delivery Systems for Tuberculosis Prevention and Treatment. 1st edn, Advances in Pharmaceutical Technology, John Wiley & Sons, Chichester West Sussex UK, pp. 258-274. https://doi.org/10.1002/9781118943182.ch13

Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs. / Das, Shyamal C.; Stewart, Peter J.

Drug Delivery Systems for Tuberculosis Prevention and Treatment. ed. / Anthony J. Hickey; Amit Misra; P. Bernard Fourie. 1st. ed. Chichester West Sussex UK : John Wiley & Sons, 2016. p. 258-274 (Advances in Pharmaceutical Technology).

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs

AU - Das, Shyamal C.

AU - Stewart, Peter J.

PY - 2016/8/26

Y1 - 2016/8/26

N2 - This chapter considers the respiratory delivery of drugs used in the treatment of tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis. It provides a rationale for respiratory delivery of anti-tubercular drugs to the lungs, including the targeting of alveolar macrophages and granulomas. The doses of anti-tubercular drugs are high and most formulations will be carrier free containing drug and limited amounts of excipient. The aerosolization of high dose drugs existing in a cohesive matrix will be related to de-agglomeration processes. The chapter outlines the studies that have occurred in this area using particle engineering approaches. Formulations of particles or engineered particles which possess a suitable size for respiratory delivery can be considered as cohesive matrices. The particles in the matrix will interact due to the various interactive forces that exist between particles, including contact potential forces, Coulombic forces, intermolecular forces, capillary force and solid bridging.

AB - This chapter considers the respiratory delivery of drugs used in the treatment of tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis. It provides a rationale for respiratory delivery of anti-tubercular drugs to the lungs, including the targeting of alveolar macrophages and granulomas. The doses of anti-tubercular drugs are high and most formulations will be carrier free containing drug and limited amounts of excipient. The aerosolization of high dose drugs existing in a cohesive matrix will be related to de-agglomeration processes. The chapter outlines the studies that have occurred in this area using particle engineering approaches. Formulations of particles or engineered particles which possess a suitable size for respiratory delivery can be considered as cohesive matrices. The particles in the matrix will interact due to the various interactive forces that exist between particles, including contact potential forces, Coulombic forces, intermolecular forces, capillary force and solid bridging.

KW - Anti-tubercular drugs

KW - Carrier free containing drug

KW - Cohesive matrix

KW - De-agglomeration processes

KW - Mycobacterium tuberculosis

KW - Particle engineering approaches

KW - Respiratory delivery

UR - http://www.scopus.com/inward/record.url?scp=85018878547&partnerID=8YFLogxK

U2 - 10.1002/9781118943182.ch13

DO - 10.1002/9781118943182.ch13

M3 - Chapter (Book)

SN - 9781118943175

T3 - Advances in Pharmaceutical Technology

SP - 258

EP - 274

BT - Drug Delivery Systems for Tuberculosis Prevention and Treatment

A2 - Hickey, Anthony J.

A2 - Misra, Amit

A2 - Fourie, P. Bernard

PB - John Wiley & Sons

CY - Chichester West Sussex UK

ER -

Das SC, Stewart PJ. Understanding the Respiratory Delivery of High Dose Anti-Tubercular Drugs. In Hickey AJ, Misra A, Fourie PB, editors, Drug Delivery Systems for Tuberculosis Prevention and Treatment. 1st ed. Chichester West Sussex UK: John Wiley & Sons. 2016. p. 258-274. (Advances in Pharmaceutical Technology). https://doi.org/10.1002/9781118943182.ch13